TS-021

CAS No. 667865-69-2

TS-021( —— )

Catalog No. M34451 CAS No. 667865-69-2

TS-021 is a selective dipeptidyl peptidase 4 (DPP-4) inhibitor with antidiabetic activity for the study of type 2 diabetes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 246 In Stock
5MG 411 In Stock
10MG 562 In Stock
25MG 866 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TS-021
  • Note
    Research use only, not for human use.
  • Brief Description
    TS-021 is a selective dipeptidyl peptidase 4 (DPP-4) inhibitor with antidiabetic activity for the study of type 2 diabetes.
  • Description
    TS-021 is a selective dipeptidyl peptidase 4 (DPP-4) inhibitor with antidiabetic activity for the study of type 2 diabetes.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    DPP
  • Recptor
    DPP-4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    667865-69-2
  • Formula Weight
    401.45
  • Molecular Formula
    C17H24FN3O5S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    S(=O)(=O)(O)C1=CC=CC=C1.C(CNC(CO)(C)C)(=O)N1[C@H](C#N)C[C@H](F)C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Vildagliptin

    Vildagliptin, previously identified as LAF237, is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs.

  • TAK-100

    TAK-100 is a potent, selective and orally active inhibitor of DPP-4 with IC50 of 5.3 nM.

  • P32/98 hemifumarate

    P32/98 hemifumarate is a dipeptidyl peptidase IV (DPP4) inhibitor with hypoglycemic properties that improves insulin sensitivity and β-cell responsiveness in the Zucker diabetic rat model, and may be useful in studies of type 2 diabetes and colitis.